10386_004_flag_800
Download Brochure
Email Updates
Testimonials
"The best setting of any partnering meeting..." David Wurtman, VP, Corporate Development, NexBio

The 7th Annual Pharmaceutical-Biotech Partnering Conference

discount
Looking for private, productive meetings with decision makers?
Evaluating potential partners, with promising drugs in the pipelines?
Preparing for patent cliff – increasing licensing activities to support near-term revenues?
Evaluating alternatives to overcome the lack of access to capital?
Leveraging your relationship with your IP Counsel to protect and extend your assets?


BioNetwork is an excellent choice over many partnering conferences you already have lined up for the year

Why BioNetwork?

Two themes define BioNetwork – one, the insightful content with 13 panels, 8 case studies and business round tables led by the most fascinating and influential industry leaders sharing best practices in partnering, licensing, and rapid due diligence. The other, insane networking! BioNetwork’s exclusivity makes 1:1 meetings and networking activities more intimate, more dynamic and fruitful, ensuring quality time with your peers and potential partners.

To view the full benefits of coming to BioNetwork, click here.
To view the full 3-day agenda, click here.
To view the networking activities, click here.

New For 2009: IP Leaders Joining BD Leaders To Ensure Successful Partnerships

With big Pharma coming to terms with the implications of patent cliff, successful leaders in business development are becoming more and more IP savvy, protecting valuable commercialized assets and giving new life to those assets that were previously shelved.

More Intellectual Property Counsel and Patent Attorneys are joining BioNetwork for the first time!
This perfect combination of BD and IP forces help drive future business growth, with both sides gaining better understanding of how your patents can be better protected and enforced. For more information on IP sessions and speakers, click here.

Key Industry Leaders Joining BioNetwork This Year Include:

  • Andrew Uprichard, President and CEO, GliaMed
  • Anne Dollard, Deputy General Counsel, Chief Patent Counsel, Takeda San Francisco
  • Carole Nuechterlein, Head, Roche Venture Fund
  • Constantine Chinaporos, Vice President Corporate Development, Genzyme
  • Karen LaRochelle, Executive Director, Strategic Transactions Group, Bristol Myers Squibb
  • Kerry Flynn, Vice President, Intellectual Property, Shire Pharmaceuticals
  • Kevin Keuhm, Vice President, Global Transactions, BD&L, Bayer Healthcare
  • Len Smith, Senior Intellectual Property Counsel, Novo Nordisk
  • Markus Ewert, Global Business Development & Licensing, Head, Search & Evaluation, Cardiovascular and Metabolism, Novartis Pharma AG
  • Martin Reeves, Vice President Business Development and Strategic Alliances, Cephalon
  • Mike Leonetti, Executive Director, Alliance Management, Boehringer Ingelheim
  • Michael Myers, Director, Global External R&D – Due Diligence, Eli Lilly & Company
  • Patrick Farley, Senior Patent Counsel, Genentech
  • Peter Joiner, Chief Executive Officer, Avinuero
  • Remis Bistras, Vice President, Business Development and Licensing, Cerimon
  • Robert Bagdorf, Vice President, Worldwide Business Development, Pfizer Inc.
  • William Lis, Vice President Business and Commercial Development, Portola Pharmaceuticals
To view the full list of speakers and the Advisory Board, click here.